Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Herceptin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Herceptin | DRUG | Given intravenously once weekly for 12 weeks prior to surgery. |
| Taxol | DRUG | Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery. |
| Adriamycin | DRUG | Given every three weeks for 12 weeks after surgery. |
| Cytoxan | DRUG | Given every three weeks for 12 weeks after surgery. |
Inclusion Criteria: * Patients must have Stage II or III histologically diagnosed breast cancer * Primary invasive breast cancers that overexpress the HER2/neu oncogene * Age older than 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of \< 1 * White blood cell (WBC) \> 4000/...
Top 20 of 92 competitors
Herceptin is used for the treatment of breast cancer. It is being studied as a neoadjuvant therapy, meaning it is given before the main treatment, in combination with Taxol for breast cancer patients. The drug is currently in Phase 2 clinical development for this indication.
Herceptin is being developed by Bristol-Myers Squibb Company, which is publicly traded under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with breast cancer.
Herceptin is in Phase 2 clinical development for breast cancer. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a clinical trial to assess its effects when used as neoadjuvant therapy.
Herceptin is being studied in one clinical trial with the identifier NCT00136539. This Phase 2 trial, titled 'Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer,' has been completed and enrolled 41 participants in the United States. The trial was not randomized or double-blind.
Herceptin is not FDA approved for breast cancer. It is an investigational drug currently in Phase 2 clinical development. The completed clinical trial, NCT00136539, evaluated Herceptin as neoadjuvant therapy, but the drug has not yet received regulatory approval.